Podcast Episodes
Back to Search
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
Episode 99
In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-…
4 years, 3 months ago
The Evolving Role of TKIs in First-line Treatment of Advanced HCC
Episode 98
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatm…
4 years, 4 months ago
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
Episode 97
In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, includin…
4 years, 4 months ago
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
Episode 96
In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving …
4 years, 4 months ago
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
Episode 95
In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-…
4 years, 5 months ago
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma
Episode 94
In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on lev…
4 years, 5 months ago
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
Episode 93
In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thec…
4 years, 5 months ago
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
Episode 92
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line t…
4 years, 5 months ago
First-Generation TRK Inhibitors: Clinical Evidence and Indications
Episode 90
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for firs…
4 years, 5 months ago
PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm
Episode 91
In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the curr…
4 years, 6 months ago